Korsana Biosciences, Inc. (NASDAQ: KRSA) is a Healthcare company (Biotechnology) with a market capitalization of $152M. The Maz Rating grades it against the other companies in its sector.
Korsana Biosciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $32.50, Korsana Biosciences, Inc. trades at 149.3x sales and 0.0x book value, with an EV/EBITDA of 5.6. Over the last twelve months it generated about $1M of revenue and a net loss of $1.6B. It runs a gross margin of 25.6%, an operating margin of -5277.3% and a net margin of -5088.4%. It shows return on equity of -50.6%, return on invested capital of -12.9% and a free cash flow yield of -33.5%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 10.42. Over the past 52 weeks the share price ranged from $7.19 to $59.36, with a beta of 1.84.
Korsana Biosciences, Inc. does not currently pay a dividend.
2 Wall Street analyst ratings cover the stock: 2 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Korsana Biosciences, Inc. is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases. Its lead program, KRSA-028, is an investigational shuttled antibody targeting amyloid beta for the treatment of Alzheimer's disease. The company became publicly traded in September 2026 through a merger with Cyclerion Therapeutics, Inc.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Korsana Biosciences, Inc. (KRSA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 10880.5% / 30% · Interest income / Revenue 184900000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 10880.5% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 184900000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 10880.5% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 184900000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 95.1% / 33.33% · Receivables / Avg Assets (4Q) 0.21% / 33.33% · Interest income / Revenue 184900000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 98.7% / 33.33% · (Cash+Recv) / Total Assets 98.7% / 33.33% · Interest income / Revenue 184900000.0% / 5% | Fail |
No. As of September 2026, Korsana Biosciences, Inc. (KRSA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Korsana Biosciences, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 184900000.0% of each dividend: Korsana Biosciences, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.